News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shareholders Support Management Proposals At SYGNIS’ AGM With Overwhelming Majority


7/21/2014 8:58:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Madrid, Spain and Heidelberg, Germany, 21 July 2014 - At the Annual General Meeting (AGM) of SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held on 17 July 2014 shareholders representing 83 percent of the capital approved all proposals of the Management with an overwhelming majority. Main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past Fiscal Year, the election of new members of the Supervisory Board, as well as the creation of new authorised capital.

Mr. Werner-Friedrich Knuth Schaefer has left the Supervisory Board. Dr. Cristina Garmendia Mendizábal, Chairwoman of the Supervisory Board thanked Mr. Werner- Friedrich Knuth Schaefer for his work and efforts for SYGNIS AG. She welcomed Mrs. Maria Jesús Sabatés Mas as new member of the Supervisory Board.

At the Annual General Meeting, Pilar de la Huerta, CEO and CFO of SYGNIS, highlighted the strategic and financial achievements during fiscal year 2013 including the completion of the restructuring measures, the launch of the first products based on SYGNIS’ proprietary technology QualiPhi® (now renamed SensiPhi®) by QIAGEN and the very successful capital increase. For the current year, Mrs. de la Huerta expects the development of further products in the field of DNA amplification and sequencing and the strengthening of SYGNIS’ position especially in the market for Next Generation Sequencing (NGS).

You will find further information about our AGM and the detailed voting results on our website: www.sygnis.com in the Investor Relations section.

For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Tel: +34 91 192 36 50
Email: pdelahuerta@sygnis.es
About SYGNIS AG: www.sygnis.com

After the merger in 2012 between X-Pol Biotech, specializing in DNA amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS’ new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, SensiPhi® and is currently developing other products in the field of Next Generation Sequencing.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES